Long-Term Correction of Murine Lipoprotein Lipase Deficiency with AAV1-Mediated Gene Transfer of the Naturally Occurring LPLS447XBeneficial Mutation

CJD Ross,J Twisk,JM Meulenberg,GQ Liu,K van den Oever,E Moraal,WT Hermens,J Rip,JJP Kastelein,JA Kuivenhoven,MR Hayden

DOI: https://doi.org/10.1089/hum.2004.15.906

2004-01-01

Human Gene Therapy

Abstract:Human lipoprotein lipase (LPL) deficiency causes profound hypertriglyceridemia and life-threatening pancreatitis. We recently developed an adult murine model for LPL deficiency: LPL-/- mice display grossly elevated plasma triglyceride (TG) levels (>200-fold) and very low high-density lipoprotein cholesterol (HDLC < 10% of normal). We used this animal model to test the efficacy of adeno-associated virus-mediated expression of hLPLS447X (AAV1-LPLS447X) in muscle for the treatment of LPL deficiency. Intramuscular administration of AAV1-LPLS447X resulted in dose-dependent expression of hLPL protein and LPL activity (up to 33% of normal murine levels) in postheparin plasma. Remarkably, visible hyperlipidemia was resolved within 1 week; plasma TG was reduced to near-normal levels (from 99.0 to 1.8 mmol/L), and plasma HDLC was increased 6-fold (from 0.2 to 1.1 mmol/L). At 8 months after administration of AAV1-LPLS447X, an intravenous lipid challenge showed efficient, near-normal clearance of plasma TG. Histologic analyses of injected muscle further indicated that abnormal muscle morphology observed in LPL-/- mice was reversed after treatment. Expression of therapeutic levels of LPLS447X, and the subsequent beneficial effect on plasma lipid levels, has lasted for more than 1 year. We therefore conclude that AAV1-mediated transfer of LPLS447X into murine skeletal muscle results in long-term near-correction of dyslipidemia associated with LPL deficiency.